A detailed history of Cetera Investment Advisers transactions in Genmab A/S stock. As of the latest transaction made, Cetera Investment Advisers holds 11,508 shares of GMAB stock, worth $235,568. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,508
Previous 8,823 30.43%
Holding current value
$235,568
Previous $221,000 26.7%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$23.84 - $28.48 $64,010 - $76,468
2,685 Added 30.43%
11,508 $280,000
Q2 2024

Aug 22, 2024

SELL
$25.13 - $30.27 $56,542 - $68,107
-2,250 Reduced 20.32%
8,823 $221,000
Q1 2024

May 24, 2024

BUY
$26.43 - $32.77 $292,659 - $362,862
11,073 New
11,073 $331,000
Q3 2023

Nov 14, 2023

SELL
$35.27 - $42.24 $28,392 - $34,003
-805 Reduced 9.47%
7,695 $271,000
Q2 2023

Aug 09, 2023

SELL
$37.4 - $42.94 $86,543 - $99,363
-2,314 Reduced 21.4%
8,500 $323,000
Q1 2023

May 15, 2023

SELL
$34.88 - $43.22 $216,290 - $268,007
-6,201 Reduced 36.44%
10,814 $408,000
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $151,491 - $210,922
4,482 Added 35.76%
17,015 $721,000
Q3 2022

Nov 10, 2022

BUY
$31.52 - $373.61 $395,040 - $4.68 Million
12,533 New
12,533 $403,000
Q1 2022

May 13, 2022

SELL
$30.95 - $39.68 $230,948 - $296,092
-7,462 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$35.87 - $47.12 $22,239 - $29,214
620 Added 9.06%
7,462 $295,000
Q3 2021

Nov 16, 2021

BUY
$41.55 - $48.72 $75,413 - $88,426
1,815 Added 36.11%
6,842 $299,000
Q2 2021

Aug 13, 2021

BUY
$32.88 - $44.57 $165,287 - $224,053
5,027 New
5,027 $205,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.